Product Program year 2025 Source: CMS Open Payments

Tryvio

Drug Hypertension

NDC 80491-8012-8

Open in the dashboard

General payments

$383,668

677 payments

Research payments

$0

0 payments

Through program year 2025, $383,668 in general payments and $0 in research payments were reported against Tryvio (Hypertension).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2025 General $91,634 413
2024 General $292,034 264

Breakdown

Who paid General payments · program years 2024–2025
  1. Idorsia Pharmaceuticals US Inc $383,668 677 payments
Top recipients General payments · program year 2025
  1. Michael Bloch Internal Medicine · Reno, NV $16,512 18% · 10 payments
  2. Todd Villines Cardiovascular Disease · Charlottesville, VA $6,875 8% · 2 payments
  3. Javed Butler Advanced Heart Failure and Transplant Cardiology · Jackson, MS $6,440 7% · 1 payment
  4. Vivek Bhalla Nephrology · Stanford, CA $5,766 6% · 6 payments
  5. Vivian Fonseca Endocrinology, Diabetes & Metabolism · New Orleans, LA $5,483 6% · 4 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Nephrology Internal Medicine $22,976 25% · 70 practitioners
  2. Internal Medicine $21,729 24% · 35 practitioners
  3. Endocrinology, Diabetes & Metabolism Internal Medicine $14,636 16% · 6 practitioners
  4. Cardiovascular Disease Internal Medicine $9,754 11% · 51 practitioners
  5. Family Medicine $6,692 7% · 14 practitioners

The top 5 of 28 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Nevada $16,512 18% · 1 recipient
  2. California $10,793 12% · 29 recipients
  3. Texas $10,595 12% · 22 recipients
  4. North Carolina $8,821 10% · 26 recipients
  5. Mississippi $8,713 10% · 28 recipients

The top 5 of 25 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

677 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record